click

Alcon Science | United States

This page is available in English. Select below for other countries.

Select other country

MEDICAL EDUCATION

Resident Education Equipment

Equipment Placement Request

 

Applications are not currently being accepted for the Equipment Placement program.

Guidelines

 

Please note the following general guidelines for equipment placement:

  • Equipment is for nonclinical, nonhuman use only in North America
  • Requesting organization must be tax exempt or government affiliated
  • Organization should be an accredited ophthalmology program (ACGME or CanERA)
  • Individual physicians and/or private practice groups are not eligible
  • An academic organization should not have received the same type of equipment within the past 24 months
  • Requests are limited to one unit per model
  • Approval of equipment placement will be communicated only when an actual piece of equipment is ready for delivery
  • Availability of equipment is limited, and placement will be prioritized based on assessment of educational need
  • Commercial associates do not make determinations of educational need or placement of equipment

 

Requirements

 

The submission must include the following information:

  • Organization’s name, address, and phone number that coordinates with the tax identification number
  • Name of program director at requesting organization, with phone number and email address for follow-up

 

Next steps

 

  • Request is reviewed by the IME Grant Office
  • Notification will be provided within 5 business days determining whether the request will be accepted for consideration
  • Status of requests will be provided to applicants in January, April, July, and October
  • Accepted requests will remain active unless notified otherwise by requesting party

 

Recent Scientific Publications

 

 

DRY EYE

 

AR-15512 Registration Clinical Studies

 

 

 

DRY EYE

 

A Review of Phase 3 Trial Results for Acoltremon (AR-15512) Ophthalmic Solution 0.003%

 

 

DRY EYE

 

AR-15512: Results of Phase 3 Studies for Acoltremon Ophtalmic Solution 0.003%, a Novel TRPM8 Agonist